{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:48:30Z","timestamp":1782200910381,"version":"3.54.5"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2025AFD777"],"award-info":[{"award-number":["2025AFD777"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974005"],"award-info":[{"award-number":["81974005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200253"],"award-info":[{"award-number":["82200253"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-SYBLD2022MS-0055"],"award-info":[{"award-number":["Y-SYBLD2022MS-0055"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019035","name":"Hubei Province Science and Technology Program","doi-asserted-by":"publisher","award":["2024AFB028"],"award-info":[{"award-number":["2024AFB028"]}],"id":[{"id":"10.13039\/501100019035","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jcyt.2026.102055","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:11:25Z","timestamp":1767975085000},"page":"102055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplant"],"prefix":"10.1016","volume":"28","author":[{"given":"Peiling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jcyt.2026.102055_bib0001","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1182\/blood.2023020075","article-title":"How I treat posttransplant lymphoproliferative disorder","volume":"142","author":"Amengual","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jcyt.2026.102055_bib0002","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102055_bib0003","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.18828","article-title":"Real-world evidence of the safety and survival with CD19 CAR-T cell therapy for relapsed\/refractory solid organ transplant-related PTLD","volume":"202","author":"McKenna","year":"2023","journal-title":"British journal of haematology"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102055_bib0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s11912-023-01418-0","article-title":"Important Considerations in the Diagnosis and Management of Post-transplant Lymphoproliferative Disorder","volume":"25","author":"Lee","year":"2023","journal-title":"Current oncology reports"},{"issue":"23","key":"10.1016\/j.jcyt.2026.102055_bib0005","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102055_bib0006","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/cam4.3686","article-title":"Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China","volume":"10","author":"Ying","year":"2021","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102055_bib0007","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.tips.2020.06.001","article-title":"Deciphering the TCR Repertoire to Solve the COVID-19 Mystery","volume":"41","author":"Gutierrez","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"10.1016\/j.jcyt.2026.102055_bib0008","doi-asserted-by":"crossref","first-page":"8995","DOI":"10.1073\/pnas.1902649116","article-title":"Select sequencing of clonally expanded CD8(+) T cells reveals limits to clonal expansion","volume":"116","author":"Huang","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"10.1016\/j.jcyt.2026.102055_bib0009","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2026.102055_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3324\/haematol.2019.245969","article-title":"Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A","volume":"105","author":"Ayuk","year":"2020","journal-title":"Haematologica"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T07:17:13Z","timestamp":1782199033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1465324926000113"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102055","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD19 chimeric antigen receptor T-cell therapy for the treatment of a patient with refractory Burkitt lymphoma after kidney transplant","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102055"}}